Abbott earns FDA green light for next-gen CardioMEMS pulmonary artery pressure reader
February 27, 2026
Abbott (NYSE: ABT)+ today the FDA approved its CardioMEMS Hero next-generation pulmonary artery (PA) pressure reader.
Abbott (NYSE: ABT)+ today the FDA approved its CardioMEMS Hero next-generation pulmonary artery (PA) pressure reader.
OXFORD, England, Feb. 26, 2026 /PRNewswire/ — Optellum, the leading AI-enabled solution for earlier lung cancer detection, is thrilled to announce that it has received Therapeutic Goods Administration (TGA) class IIb approval in Australia for the Virtual Nodule Clinic (VNC) platform to support early lung cancer diagnosis.
Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically “cold,” meaning they do not attract enough immune cells to mount a strong attack.
A Phase I clinical trial published in The Lancet has shown that combining stem cell therapy with standard fetal surgery before birth is a safe and promising approach to treat myelomeningocele, a severe form of spina bifida.
Learn how a new laser-based therapy is giving patients with aggressive brain cancer a stronger chance at survival.
Learn more about Pico-C, a tool that helps reveal the genome’s structure during the first days of life.
TORTOLA, British Virgin Islands, Feb. 25, 2026 /PRNewswire/ — Cara Medical Ltd. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the CARA System, a computed tomography angiography (CTA)-based platform that provides noninvasive, patient-specific three-dimensional (3D) visualization of the cardiac conduction system.
PARSIPPANY, N.J., Feb. 25, 2026 /PRNewswire/ — Scopio Labs today announced it has achieved IVDR certification from BSI, a major regulatory milestone that clears the path for its AI-driven digital morphology platforms in the European Union
ZURICH, Feb. 25, 2026 /PRNewswire/ — Polaroid Therapeutics (PTx) today announces that POLTX_Fiber™ has received the CE Mark as a Class IIb medical device with APT™ (Antimicrobial Polymer Technology).
DALLAS, Feb. 25, 2026 /PRNewswire/ — 4WEB Medical, an orthopedic implant company focused on developing innovative implants that utilize its proprietary TRUSS Implant Technology™, announced that it has received 510(k) clearance to market its SI Joint Truss System™.